Teva Appoints Carlo De Notaristefani As President And CEO Of Global Operations

Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has appointed Carlo De Notaristefani as President and Chief Executive Officer of Global Operations.

De Notaristefani has over 25 years of international experience with extensive technical, operational, manufacturing and P&L experience. Recently, De Notaristefani was at Bristol Myers Squibb (BMS) where he served as President, Technical Operations and Global Support Functions.

The company also appointed Aharon Yaari as the Executive Vice President to the newly created organization, Community and Institutional Affairs. Yaari joined Teva in 1981, and has served in significant key positions at Teva, such as Group Vice President, Global API, and most recently as Group Vice President, Teva Generics Systems.

In addition, as part of its strategic objectives, Teva has established an organization of Community and Institutional Affairs. This organization will be led by Yaari who will execute on Teva's global commitment to social responsibility, philanthropy, institutional affairs and academic relations.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT